FDA approves first drug for neurological symptoms in Type 3 Gaucher disease
Adults and children weighing at least 15 kg are eligible for Infilbray. In a 52-week trial, the tablets outperformed enzyme replacement therapy on a combined measure of muscle coordination and thinking.
Numbers in brackets link to the sources listed below.
On 18 November the US Food and Drug Administration approved Infilbray, the first drug for neurological symptoms in Type 3 Gaucher disease[1U.S. Food and Drug AdministrationFDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher DiseaseOpen sourceSources [1]]. The approval covers venglustat tablets for adults and children weighing at least 15 kg[1U.S. Food and Drug AdministrationFDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher DiseaseOpen sourceSources [1]].
In this rare inherited condition, an enzyme fails to break down certain fatty substances properly, allowing them to build up in the brain and elsewhere in the body[1U.S. Food and Drug AdministrationFDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher DiseaseOpen sourceSources [1]]. Patients can develop problems with balance, speech and memory that worsen over time[1U.S. Food and Drug AdministrationFDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher DiseaseOpen sourceSources [1]]. Infilbray can pass from the bloodstream into the brain and reduce the buildup there[1U.S. Food and Drug AdministrationFDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher DiseaseOpen sourceSources [1]].
The phase 3 trial, called LEAP2MONO, enrolled 43 patients aged 12 or older whose disease outside the nervous system had stabilized with enzyme replacement therapy[2Pharmacy TimesFDA Approves Venglustat, First Treatment for Neurological Symptoms of GD3Open sourceSources [2]]. Researchers randomly assigned participants to take a tablet daily or receive enzyme replacement by infusion every two weeks[1U.S. Food and Drug AdministrationFDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher DiseaseOpen sourceSources [1]].
After 52 weeks, the tablet group did better on a measure that combined tests of muscle control and coordination with an assessment of thinking[1U.S. Food and Drug AdministrationFDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher DiseaseOpen sourceSources [1]]. Sanofi reported that the difference was statistically significant (p=0.0137)[3SanofiSanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher diseaseOpen sourceSources [3]].
The FDA listed digestive symptoms and changes in mood among the most commonly reported side effects[1U.S. Food and Drug AdministrationFDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher DiseaseOpen sourceSources [1]]. The agency also cited reports of serious psychiatric effects, including suicidal thoughts and behavior[1U.S. Food and Drug AdministrationFDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher DiseaseOpen sourceSources [1]].
Sources
- 1FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
PrimaryU.S. Food and Drug AdministrationAccessed
- 2FDA Approves Venglustat, First Treatment for Neurological Symptoms of GD3
IndependentPharmacy TimesAccessed
- 3
ITANU’s newsroom system produced this article with AI and checked it against the sources listed above. How we work

